Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73338
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73338
Character Range: 13365–14677

73338              A test of tumour tissue from a patient with metastatic colorectal cancer (stage IV), requested by a specialist or consultant physician, to determine if:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    362.60
                     (a) requirements relating to rat sarcoma oncogene (RAS) gene variant status for access to cetuximab or panitumumab under the Pharmaceutical Benefits Scheme are fulfilled, if:
                       (i) the test is conducted for all clinically relevant mutations on KRAS exons 2, 3 and 4 and NRAS exons 2, 3, and 4; or
                       (ii) a clinically‑relevant RAS variant is detected;

                     and, in cases where no RAS variant is detected:
                     (b) the requirements relating to BRAF V600 gene variant status for access to encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.